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Background: The discovery of malaria transmission-blocking compounds is seen as key to malaria elimination
strategies and gametocyte-screening platforms are critical filters to identify active molecules. However, unlike
asexual parasite assays measuring parasite proliferation, greater variability in end-point readout exists between
different gametocytocidal assays. This is compounded by difficulties in routinely producing viable, functional and
stage-specific gametocyte populations. Here, a parallel evaluation of four assay platforms on the same gametocyte
populations was performed for the first time. This allowed the direct comparison of the ability of different assay
platforms to detect compounds with gametocytocidal activity and revealed caveats in some assay readouts that
interrogate different parasite biological functions.
Methods: Gametocytogenesis from Plasmodium falciparum (NF54) was optimized with a robust and standardized
protocol. ATP, pLDH, luciferase reporter and PrestoBlue® assays were compared in context of a set of 10 reference
compounds. The assays were performed in parallel on the same gametocyte preparation (except for luciferase
reporter lines) using the same drug preparations (48 h). The remaining parameters for each assay were all comparable.
Results: A highly robust method for generating viable and functional gametocytes was developed and comprehensively
validated resulting in an average gametocytaemia of 4 %. Subsequent parallel assays for gametocytocidal activity
indicated that different assay platforms were not able to screen compounds with variant chemical scaffolds
similarly. Luciferase reporter assays revealed that synchronized stage-specific gametocyte production is essential
for drug discovery, as differential susceptibility in various gametocyte developmental populations is evident.
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Conclusions: With this study, the key parameters for assays aiming at testing the gametocytocidal activity of potential
transmission blocking molecules against Plasmodium gametocytes were accurately dissected. This first and uniquely
comparative study emphasizes differential effects seen with the use of different assay platforms interrogating variant
biological systems. Whilst this data is informative from a biological perspective and may provide indications of the drug
mode of action, it does highlight the care that must be taken when screening broad-diversity chemotypes with a
single assay platform against gametocytes for which the biology is not clearly understood.
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Global efforts to eliminate malaria have achieved success
in Europe and North America, but the disease remains a
major health problem in sub-Saharan Africa [1]. Mortality
rates have been reduced due to the deployment of
insecticide-treated bed nets, indoor residual spraying and
artemisinin-based combination therapy (ACT), but an
estimated 198 million cases still occurred in 2013 [1]. One
of the major realizations from previous elimination
attempts is that, compared to smallpox and poliomyelitis,
no single strategy will be applicable to control and
eliminate malaria. Particularly evident is the fact that
malaria elimination will not be achieved by focusing only
on the treatment of the disease in humans or on vector
control, but will require strategies to prevent transmission
of the parasite between the human host and mosquito
vector by targeting hepatic and gametocyte developmental
stages [2, 3]. In 2007, the malaria eradication agenda was
adopted by the global malaria community to galvanize co-
ordinated efforts aimed not only to control malaria but
also to eliminate it world-wide and ultimately eradicate
this disease [1].
As pathogens, parasites of the genus Plasmodium have
exquisitely adapted to varying biological environments
in their human and mosquito hosts, with Plasmodium
falciparum parasites causing the most virulent form of
the disease. Anopheles mosquitoes introduce sporozoites
into humans and these infect hepatocytes where, un-
detected, they replicate en masse and are released to
initiate the pathogenic asexual cycle in human erythro-
cytes. Synchronized egress of merozoites from erythro-
cytes results in characteristic fever spells that typify the
disease [4]. A portion of these P. falciparum parasites
mature through five distinctive stages (I-V) into sexual
forms in a process known as gametocytogenesis, lasting
~8 to 12 days, after which mature stage V male and
female gametocytes are transmitted to mosquitoes for
sexual reproduction [4, 5]. Mosquito uptake initiates
important molecular and cellular changes in the gameto-
cytes, enabling adjustment from the human to insect
host. Contact with midgut factors activates the develop-
mentally arrested gametocytes, resulting in egress from the
erythrocyte, gamete formation and subsequent fertilization[6]. This is followed by the transformation of the fertilized
zygote into the infective ookinete and oocyst that releases
sporozoites for transmission back to humans [7].
Commitment to sexual development is postulated to
take place in the first 20 h of the preceding erythrocytic
cycle [8]. All merozoites from a single schizont will
become either male or female gametocytes [9] with gen-
der predetermined in the schizont committed to game-
tocytogenesis, but it is typically female-biased [10, 11].
Gametocyte production generally increases when the
human host is anaemic with a low haematocrit and reti-
culocytosis [12].
Several population bottlenecks occur during the
complete Plasmodium life cycle including the sexual
developmental stages in the mosquito (e.g. only ~10
oocysts in mosquito midguts) as well as the hepatic
sporozoite and intra-erythrocytic sexual gametocyte
stages in humans. These, therefore, represent critical
areas that could be successfully targeted for the ambi-
tious goal of malaria elimination [13, 14]. However,
given that a strategy to target the vector stages would
require a drug to be at pharmacologically relevant
concentrations for as long as mature gametocytes cir-
culate (up to 30 days), the most appropriate point of
intervention is to target the host gametocytes and
eliminate the parasite population thus interrupting
transmission. Currently, only artesunate, artemether
and primaquine have therapeutic activity against late stage
gametocytes, but these are threatened by emerging resist-
ance and toxicity concerns (e.g. for primaquine in G6PD
deficient patients) [15]. The development of new gameto-
cytocidal compounds has therefore become a priority.
Standard mosquito membrane-feed assays remain
the ultimate indicator of transmission-blocking ability
of new compounds against P. falciparum parasites, but
due to the highly demanding nature of this approach,
gametocyte assays are key filters to identify transmission-
blocking molecules [15]. However, there is a lack of
standardization of methods to produce gametocytes and
of assays to screen compounds. This makes it difficult to
compare results from different laboratories and has
hampered the discovery of new chemotherapeutics target-
ing gametocytes. The in vitro production of pure, viable,
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and in a consistent, reproducible manner for down-
stream screening assays is challenging and several
methods have recently been published [15–21]. Game-
tocytogenesis was induced by nonspecific ‘stress’ to the
parasite, including a drop in haematocrit [22], the use
of ‘spent’ nutrient deficient culture medium [19], lympho-
cytes [23], mammalian hormones [24], reticulocytes [25],
some inhibitors of nucleic acid synthesis (including antifo-
lates) [22, 26, 27], Berenil, Fansidar, chloroquine, amodia-
quine, sulphadoxine-pyrimethamine, ammonia compounds
[28-30] and cholera toxin [12]. However, many of these
methods are cumbersome, costly, not robust, and the
gametocytes may not be suitable for evaluating potential
transmission-blocking compounds.
Gametocyte screening assays should be reproducible
and amenable to scaling up to medium- or high-
throughput systems. Since gametocytocidal activity can-
not be monitored with cellular multiplication markers,
recent screens have typically relied on phenotypic assays.
Systems developed thus far range from determination of
gametocyte viability through detection of ATP [21, 31–33]
and parasite lactate dehydrogenase (pLDH) [34, 35],
colourimetric detection [31, 32, 36–38], flow cytometry
[39] and transgenic reporter lines, which are useful for
monitoring stage-specific effects [37, 40]. Some of these
assays have been developed into reproducible medium- to
high-throughput assays [38, 41, 42]. However, since these
assays interrogate different metabolic pathways in the
parasite, notable discrepancies in the outputs regarding
the identification of compounds with gametocytocidal ac-
tivity have been observed in the literature. Potential target
compounds may therefore be missed if only one assay sys-
tem is used. Direct comparison of assay platforms using a
reference set of gametocytocidal compounds has not been
reported yet. This could be highly informative to evaluate
the robustness and validity of individual assay platforms in
drug discovery programmes.
Here, a system for the production of gametocytes is
reported that addresses several issues including: 1) in-
creasing the number of parasites that commit to game-
tocytogenesis; 2) isolating large numbers of pure and
viable parasites of a specific stage of gametocytes, and 3)
reducing variability in gametocyte production, resulting
in a robust system. Moreover, these gametocytes were
subsequently used in a comparative study of four different
assay systems on a single set of anti-malarial compounds
provided by the Medicines for Malaria Venture (MMV).
The ability of compounds to inhibit gametocytes was mea-
sured by detecting changes in the redox status of the
parasite (modified alamarBlue® assay [31, 41]), energy
production (measurement of ATP levels [21, 32, 33, 36]),
active glycolysis reflecting metabolic activity (pLDH [34])
and stage-specificity with a luciferase reporter assay [37].Uniquely, all of the assays were performed on the same
gametocyte population, with the same drug pressure
applied for 48 h. This work enabled interrogation of the
biological consequence of gametocytocidal compounds,
irrespective of assay platform influences.Methods
In vitro cultivation of asexual stage Plasmodium
falciparum parasites
In vitro P. falciparum parasite cultures were main-
tained at 37 °C in human erythrocytes at a haematocrit
of 5 % (ethics approvals: University of Pretoria
120821–077, CSIR Ref 10/2011, University of the
Witwatersrand M130569) suspended in complete cul-
ture medium [RPMI 1640 medium (Sigma-Aldrich)
supplemented with 25 mM HEPES (Sigma-Aldrich),
0.2 % D-glucose (Sigma-Aldrich), 200 μM hypoxanthine
(Sigma-Aldrich), 0.2 % sodium bicarbonate, 24 μg/ml
gentamicin (Invitrogen)] with either 0.5 % AlbuMAX® II
(Invitrogen) or 10 % human serum (Interstate Blood Bank,
Chicago, USA) and flushed with 90 % N2, 5 % O2, and 5 %
CO2 (Afrox, Johannesburg, South Africa) as described
elsewhere [43, 44]. Medium was aspirated daily and
replaced with fresh medium pre-warmed to 37 °C and
parasite proliferation was monitored with microscopy of
Giemsa-stained smears. Various P. falciparum strains
(NF54, 3D7, FCR3, W2, HB3 and 7G8) were cultured in
the same manner. In cases where asexual synchronicity
was required, standard 5 % D-sorbitol synchronization
was applied to ring-stage parasites [18].Induction of gametocytogenesis and maintenance of
gametocyte cultures
This method was adapted from Carter et al. [45]. Game-
tocytogenesis was induced by a combination of nutrient
starvation and a drop in haematocrit. Asexual parasites
were cultured to a 6–10 % parasitaemia, which was then
decreased to 0.5 % (at 6 % haematocrit) and the culture
transferred to glucose-free medium. Cultures were main-
tained in an atmosphere of 5 % CO2, 5 % O2 and
90 % N2, at 37 °C, without shaking. Cultures were also
kept at 37 °C during daily medium changes. After 72 h,
the haematocrit was dropped to 3 % (day 0). Gametocy-
togenesis was subsequently monitored microscopically
with daily medium (glucose-free) changes. On days 6–9,
residual asexual parasites were eliminated by continuous
50 mM N-acetyl glucosamine (NAG), Sigma-Aldrich)
treatment, now in the presence of 0.2 % glucose.
Glucose enrichment was maintained from day 10 on-
wards and gametocytes monitored daily by microscopy
until they were predominantly stage V and were used in
the various assays.
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Gametogenesis was assessed by treating samples with
50 μM xanthurenic acid (Sigma-Aldrich) in exflagellation
buffer (RPMI 1640 with 25 mM HEPES, 0.2 % sodium
bicarbonate, pH 8.0) followed by a >15 min incubation at
room temperature. Exflagellation was visualized by phase
contrast microscopy at 40x magnification.
Validation of stage-specific gametocyte production
Flow cytometry and cell sorting
Flow cytometry was used to distinguish asexual para-
sites from different gametocyte populations. Gameto-
cytes were enriched on CS-columns by magnetic
separation in a VarioMACS magnetic system (Miltenyi
Biotec) according to the manufacturer’s recommenda-
tions. Parasites were stained with Thiazole Orange
(1 μM) for 20–30 min in the dark at 37 °C. Flow
cytometry acquisition was performed for at least 50
000 events with a Beckman Coulter Gallios flow cyt-
ometer (TO: excitation at 488 nm; emission with 525/
40 bandpass filter at 525 ± 20 nm). Gating of unin-
fected and infected erythrocytes was previously estab-
lished and confirmed by Giemsa-stained microscopy
of sorted populations. Uninfected erythrocytes were
used as the negative control to determine background
DNA fluorescence. Post-acquisition analyses were per-
formed with Beckman Coulter Kaluza (v1.1) software.
Semi-quantitative RT-PCR
Real-time RT-PCR was used to confirm the gametocyte
stages by evaluating differential transcript abundance in
different gametocyte populations compared to asexual
parasites, using primers for asexual and gametocyte-
specific genes. Analysis was performed using the Light-
Cycler® 480 and KAPA SYBR Fast qPCR kit (Kapa
Biosystems, USA) on 18 transcripts of interest (Primer
sequences provided in Additional file 1: Table S1) using
5 pmol of each primer in 384-well plates; with cycling
after pre-incubation at 95 °C for 10 min for 45 cycles
(95 °C for 3 s, 55 °C for 7 s and 72 °C for 4 s). Relative
expression was calculated using LightCycler® 480 soft-
ware (version 1.5) and the comparative CT (2
-ΔΔCT)
method used to analyse transcript abundance.
Gametocytocidal activity assays
Anti-malarial compounds/drugs
A 10-compound set was provided by the MMV, blinded
until after data analysis. All other drugs were purchased
from Sigma-Aldrich. Compounds were dissolved in
DMSO and diluted fresh for each assay with glucose-
rich complete culture medium to achieve a final concen-
tration of 1 μM (final DMSO concentration ≤ 0.5 %). All
assays were performed in parallel using the same stock
of compounds, diluted fresh at the same time under thesame conditions. Gametocytocidal activity was controlled
by H2O2 (0.5 % continuous or 200 mM added at end-
point) as well as drug controls, including methylene blue
(1 μM) and dihydroartemisinin (DHA) (1 μM). Untreated
gametocytes and uninfected red blood cells or culture
medium were used to monitor viability and background,
respectively.
Resazurin-based dye assay
The PrestoBlue® (Life Technologies) assay was based on an
adaptation of the method described by Tanaka and
colleagues [31, 41]. Drug dilutions were placed in triplicate
in 96-well plates in a volume of 50 μl/well. Semi-
synchronous gametocyte cultures (50 μl/well, stage IV/V)
were added to the 96-well plates to achieve a final gameto-
cytaemia and haematocrit of 2 % and 5 % respectively, in a
total incubation volume of 100 μl. The plate was placed
on a shaker for 10–20 s before being encased in an air-
tight chamber and gassed for 5 min with a 5 % CO2, 5 %
O2, balance N2 mixture (Afrox, Johannesburg, South
Africa). Following incubation at 37 °C for 48 h, 10 μl of
PrestoBlue® reagent was added to each well, the plate
mixed on a shaker for 10–20 s and left to incubate at
37 °C for 2 h. Finally, the plate was centrifuged at
120xg (1 min), and 70 μl of the supernatant transferred
to a clean 96-well plate before reading in a multiwell
spectrophotometer (Infinite F500, Tecan, USA) by
fluorescence detection at 612 nm.
pLDH assay
Drug dilutions were placed in triplicate in 96-well plates
in a volume of 100 μl/well. Semi-synchronous stage IV
and V gametocyte cultures (100 μl/well) were added to the
96-well plates to achieve a final gametocytaemia and
haematocrit of 2 % and 1 % respectively, in a total incuba-
tion volume of 200 μl. The plates were incubated at 37 °C
for 48 h. Gametocyte viability was determined spectro-
photometrically by measuring the activity of pLDH [34],
according to a modified version of the method of Makler
and Hinrichs [46]. Briefly, 100 μl of Malstat reagent
(0.21 % v/v Triton-100; 222 mM L-(+)-lactic acid;
54.5 mM Tris; 0.166 mM 3-acetylpyridine adenine
dinucleotide (APAD; Sigma-Aldrich); adjusted to pH 9
with 1 M NaOH) was transferred into a clean 96-well
plate. A fixed volume of 20 μl parasite suspension/well
was added to the Malstat plate, followed by the addition of
25 μl PES/NBT (1.96 mM nitro blue tetrazoliumchloride
NBT; 0.239 mM phenazine ethosulphate PES). Absorbance
was measured with a Multiskan Ascent 354 multiplate
scanner (Thermo Labsystems, Finland) at 620 nm.
ATP bioluminescence assay
Mature gametocytes, predominantly stage V, were
enriched using density gradient centrifugation and
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gametocytes were pelleted and resuspended in 10 ml
of glucose-rich complete medium, loaded onto 5 ml
preheated (37 °C) NycoPrep™ 1.077 cushions (Axis-
Shield) and centrifuged at 800xg for 20 min at 37 °C.
The gametocyte-containing bands were collected, con-
centrated by centrifugation and the pellet resuspended
in 5 ml glucose-rich complete medium. This was
loaded on equilibrated LS-columns for magnetic
separation in a MidiMACS magnetic system (Miltenyi
Biotec) to purify and enrich the gametocytes, which
were counted in a Neubauer chamber. Drug dilutions
were placed in triplicate in 96-well plates. Approxi-
mately 30,000 gametocytes in glucose-rich complete
medium were added to each well in a final volume of
100 μl and the plates incubated for 48 h in a humidified
gas chamber (90 % N2, 5 % O2, and 5 % CO2) at 37 °C.
Subsequently, the BacTiter-Glo™ assay (Promega) was
performed according to the manufacturer’s instructions at
room temperature in the dark, with assay substrate incu-
bation for 10 min and shaking for the first two minutes, to
detect ATP levels. Bioluminescence [17, 21, 32] was de-
tected at an integration constant of 0.5 s with the GloMax®-
Multi + Detection System with Instinct® Software.
Luciferase reporter assay
The Luciferase reporter assay was established to enable
accurate, reliable and quantifiable investigations of the
stage-specific action of gametocytocidal compounds for
each of the early and late gametocyte marker cell lines;
NF54-PfS16-GFP-Luc and NF54-Mal8p1.16-GFP-Luc
(kind gift from David Fidock, Columbia University,
USA) [37]. Gametocytogenesis was induced on synchro-
nized asexual parasites as described above, with the
exception that NAG treatment was initiated from day 1
– 4 to remove asexual parasites early and allow more
synchronized early stage gametocytes. Drug assays were
set up on day 5 and 10 (representing early stage I/II/III
and mature stage IV/V gametocytes, respectively). In
each instance, assays were set up in triplicate using a
2 % gametocytaemia, 2 % haematocrit culture and 48 h
drug pressure in a gas chamber (90 % N2, 5 % O2, and
5 % CO2) at 37 °C. Luciferase activity was determined in
20 μl parasite lysates by adding 50 μl luciferin substrate
(Promega Luciferase Assay System) at room temperature
and detection of resultant bioluminescence at an integra-
tion constant of 10 s with the GloMax®-Multi + Detection
System with Instinct® Software.
Data analysis
Assay quality was measured for all assays by defining the
standard deviation (SD); standard error of the mean
(SEM); percent coefficient of variation (%CV); signal to
background ratio (S/B), signal to noise ratio (S/N) andthe Z’-factor, which were calculated according to the for-
mulae below [34]. The Z’-factor is a measure of statis-
tical effect size. The result is given as a numerical value
(0 to 1), being more favourable as it approaches 1 [32,
47]. %CV is acceptable at <20 % [48]. All parameters
were calculated from at least three independent experi-
ments for each assay, each time performed in triplicate.
Results were expressed as the percentage inhibition
compared to untreated controls.









%CV ¼ SD=Meanð Þx 100




  x 100
%Inhibition ¼ 100– %viabilityð Þ
Results
Optimization of P. falciparum gametocyte production
Various parameters were investigated for their ability to
influence gametocyte production including: 1) the influ-
ence of stationary versus shaking culturing conditions;
2) AlbuMAX® II vs human serum in culture medium; 3)
evaluating different methods for removal of asexual
parasites; and 4) evaluating strain-specific differences in
gametocyte production (Table 1). This resulted in the
following optimized protocol.
Physiological stress was applied to a starting asexual
culture by increasing parasitaemia to 6–10 % in a para-
site population of >80 % rings. Gametocytogenesis was
subsequently induced by a combination of both nutrient
starvation (glucose deprivation) and a decrease in haem-
atocrit under stationary culturing conditions in the
presence of AlbuMAX® II and gentamicin, whilst main-
taining a 37 °C environment throughout (Table 1).
Gametocytogenesis required growth under stationary
conditions, from asexual cultures grown either under
stationary or shaking conditions. Once gametocytes were
observed microscopically, asexual parasites were re-
moved from a predominantly stage II gametocyte popu-
lation by applying NAG pressure for at least two asexual
developmental cycles (from day 6–9), whilst maintaining
gametocyte viability in a nutrient rich environment by
adding glucose. This optimized protocol produced an
average gametocytaemia of 5.1 ± 1.0 % on day 11. More-
over, a gametocyte conversion factor of 33.3 ± 1.9 % was
obtained, indicating a high proportion of asexual para-
sites committed to gametocytogenesis (Table 1). This
procedure was moreover highly robust as validated
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generated high quality, viable gametocytes in a high
average yield of 3.9 ± 0.2 %.
The addition of the broad-spectrum gentamicin to the
culture medium as preservative did not influence gameto-
cyte production or viability (normal exflagellation and
ATP production; Additional gametocyte viability indica-
tors are provided in Additional file 2: Figure S1). However,
gentamicin might influence downstream anti-malarial
assays, particularly in the context of screening unknown
test compounds. To investigate gentamycin interference,
the viability of mature stage IV-V gametocytes grown in
the presence and absence of gentamicin was determined
after treatment with dihydroartemisinin (DHA). Treat-
ment in the presence of gentamicin revealed the expected
dose–response indicating no detrimental effect of genta-
micin under these conditions and for this compound.
Gentamicin was therefore included in the culture medium
(Additional gametocyte viability indicators are provided in
Additional file 2: Figure S1).
The kinetics of conversion to gametocytes followed the
expected maturation to stage IV-V gametocytes achieved
at day 10–12 (Fig. 1b). Asexual parasitaemia peaked at day
2 at ~5 %, where after this rapidly decreased on day 7 afterTable 1 Induction of in vitro gametocytogenesis in P. falciparum pa
Conditions
Shaking vs. stationary (serum medium)
Asexual culture Gametocyte culture
Stationary Stationary
Shaking Stationary
Medium composition (asexual, stationary gametocyte cultures)















ND not detected / determined, NA not applicable
a Day 11 after induction
b Conversion factor ¼ Number of stage 2 gametocytes on day 4Number of rings on day 2 $$ \mathrm{Conversion}\ \ma
\mathrm{stage}\ 2\ \mathrm{gametocytes}\ \mathrm{on}\ \mathrm{day}\ 4}{\mathrm
Data are representative of (n) biological experiments, each performed in triplicate, ±NAG pressure. Sexual forms were visible from day 2 on-
wards, with peak gametocytaemia of ~5 % obtained on
day 11 (Fig. 1b). The viability of parasites produced on the
optimized protocol was confirmed with an ATP assay
(Additional gametocyte viability indicators are provided in
Additional file 2: Figure S2).
As previously reported, gametocytogenesis is strain
dependent and this held true for the strains that were
tested, where the ability to produce gametocytes varied
under the same optimized culture conditions [19]. Of
the P. falciparum strains tested, drug sensitive NF54 para-
sites remained superior in producing gametocytes, with
the chloroquine-resistant W2 strain, the chloroquine-
sensitive and sulphadoxine-resistant 3D7 strain, and the
chloroquine- and antifolate-resistant 7G8 strain producing
low levels of gametocytes (Table 1). No detectable gameto-
cytes were observed in the pyrimethamine resistant HB3
strain and in the FCR3 strain, which is resistant to chloro-
quine and cycloguanil (Table 1). Maximal gametocytogen-
esis (1.5 % gametocytaemia, 11 % conversion factor) could
only be achieved in freshly thawed 3D7 parasites and this
decreased as parasites were kept in routine culture for
more than 7 generations to 0.1 % gametocytaemia (~4 %
conversion rate). For optimal gametocyte production onrasites under various conditions
Gametocytaemiaa Conversion Factorb
1.3 ± 0.6 % (n = 4) 15.8 ± 0.6 %
3.3 ± 1.4 % (n = 22) 34.2 ± 3.4 %
5.1 ± 1.0 % (n = 10) 33.3 ± 1.9 %
1.9 ± 0.8 % (n = 3) 8.2 ± 2.2 %
3.7 ± 1 (n = 3) 22.7 ± 1.1 %
1.3 ± 0.6 % (n = 4) 20.7 ± 3.3 %
5.3 ± 0.2 % (n = 2) 32.3 ± 1.4 %
4.9 ± 1.0 % (n = 2) 37.7 ± 1.7 %
4.9 ± 1.0 % (n = 3) 35.0 ± 1.7 %
1.5 ± 0.2 % (n = 3) 11.2 ± 2.0 %
1.1 ± 0.2 % (n = 3) 8.9 ± 0.5 %
1 ± 0.7 % (n = 2) ND
0 % (n = 3) NA
0 % (n = 3) NA
thrm{factor}=\kern0.5em \frac{\mathrm{Number}\ \mathrm{of}\
{Number}\ \mathrm{of}\ \mathrm{rings}\ \mathrm{on}\ \mathrm{day}\ 2} $$
SEM. Data indicate maximal levels of gametocytaemia obtained
Fig. 1 Evaluation of P. falciparum gametocyte production. Parasites (NF54 P. falciparum) were cultured in medium with 0.5 % AlbuMAX for both
asexual and gametocyte cultures. a Box and whisker plots of gametocytaemia (% stage III-V gametocytes) obtained with the same optimized protocol
across three independent sites (site 1 n = 6; site 2 n = 17; site 3 n = 14). b Kinetics of parasitaemia (asexual stages; dashed line) and gametocytaemia
(gametocytes; solid line) during gametocytogenesis. The number of asexual forms increased up to maximum parasitaemia on days 2–6 (prior to NAG
treatment). Sexual forms were first detected on day 2, with gametocytaemia reaching an average of 5 % on day 11. Data are from ≥4 independent
biological experiments each performed in triplicate, ± SEM
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thawed asexual cultures within 2–3 generations after
thawing but never from asexual parasites maintained
for more than 6–9 generations.
Validation of stage-specific gametocyte production
The production of gametocytes, synchronized to a
small stage-specific window, is important in gametocy-
tocidal drug discovery efforts, as evidence indicates
differential susceptibility of gametocytes in different
stages of development towards a variety of compounds
[37, 38]. Stage-specific gametocyte production was
ensured through the use of synchronized (>80 % rings)
starting populations of asexual parasites and the appli-
cation of NAG pressure at defined time points during
gametocytogenesis. Developmental stages of gameto-
cytes were evaluated morphologically based on the
description of Hawking, 1971 (Fig. 2a) [49]. Synchron-
icity was quantified to >91 % mature stage IV/V game-
tocytes (91 ± 18 %, n ≥ 6) with <10 % contaminating
early stage (II and III) gametocytes (Fig. 2b). This syn-
chronicity was validated with semi-quantitative PCR
based on the expression of certain transcripts in a
stage-specific manner during gametocytogenesis [50].
The relative expression of a subset of 18 unique tran-
scripts, chosen for their presence in early vs. mature
gametocytes, was monitored during different stages of
gametocyte development and compared to the expres-
sion levels of these transcripts in asexual parasites as an
expression background (Fig. 2c). This allowed differen-
tiation between gametocyte stages, particularly also
allowing distinction and quantification of stage IVgametocytes from their mature stage V partners, where
certain transcripts (e.g. PF3D7_0621400) are strongly
activated and expressed in stage IV parasites, but not so
in stage V parasites compared to others solely expressed
in stage V parasites (e.g. PF3D7_0411700). These data
could be informative regarding the stage-specific de-
lineation of drug action and could allow investigations
of the kinetics of drug action enabling therapeutic
window of susceptibility descriptors.
The viability and functionality of the gametocyte
populations were confirmed by real time microscopic
observation of male gamete exflagellation induced by
xanthurenic acid and a decrease in temperature (Fig. 3a).
Moreover, the mature gametocyte populations produced
mimicked the in vivo female bias [8] with a 4:1 ratio
of female:male gametocytes produced, as evaluated
morphologically.
Flow cytometry was used as explorative technology
to differentiate and quantify gametocyte populations.
Asexual parasites were easily distinguishable from
gametocytes and additionally various gametocyte popu-
lations (stages) could be identified based on their mor-
phological and density differences (Fig. 3b). Subsequent
gating of various populations within the enriched
gametocyte sample allowed cellular sorting of between
100,000 and 5,000,000 cells. Samples were analysed
microscopically to confirm identity of the suggested
populations and discriminate between asexual and
gametocyte populations. Additionally, to distinguish the
mature male and female gametocytes, ~500,000 cells
were treated with xanthurenic acid to induce gameto-
genesis. This produced two separate gamete populations
Fig. 2 Stage-specific, quantitative analysis of gametocyte populations. a Giemsa-stained smears indicating morphology of different stages. b Stage
distribution of gametocyte populations for 22 independent gametocyte cultures. c Semi-quantitative RT-PCR of stage-specific expression of 18
unique descriptors. PCR was performed and data normalized to cyclophillin as household expression control and expressed as fold change relative to
background expression of the transcripts in asexual parasites. Data are from ≥4 independent biological experiments each performed in triplicate, from
which expression ratios were determined. Under-expressed transcripts are presented in green and over-expressed transcripts in red
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distinguishable (Fig. 3b). Although informative from a
qualitative point of view regarding quality control for
gametocyte production, the flow cytometric method is
however not amenable to continuous application in a
screening programme.Assays for gametocytocidal activity
Four different gametocytocidal screening assays were
evaluated and compared on mature stage IV-V gameto-
cytes. The assays were chosen based on their ability to
detect different biological activities as indicators of
parasite viability. The bioluminescent ATP assay reflects
energy status; pLDH is an indicator of active glycolysis;
the colourimetric resazurin dye is a redox indicator
and the luciferase reporter assays (under control of
gametocytogenesis-specific promoters for Pfs16 and
mal8p1.16) determine stage-specific action of gameto-
cytocidal compounds. Assay performance was evalu-
ated for linearity, detection range, reproducibility and
the assay screening window coefficient (Z’-factor) [48]
and inter-assay reproducibility via %CV [51]. Moreover,
drug incubation time (24 or 48 h), optimal haematocritand optimal gametocytaemia were determined for each
assay platform.ATP assay as indicator of parasite viability
The bioluminescent ATP assay measured luciferin-
luciferase as an indicator of parasite viability, directly
correlating ATP levels to luminescence output. Because
ATP is present in erythrocytes, the assay requires almost
100 % pure gametocytes that are free of contaminating,
uninfected red cells. The assay proved to be linear
over the range of 4000 – 62,000 purified gameto-
cytes (R2 = 0.99). S/N and S/B were high at >15,000
fold and >500 fold, respectively (Gametocytocidal
assay metrics provided in Additional file 3: Figure
S3). The assay was routinely performed on 30,000
gametocytes and 24 h drug treatment. Mature stage
IV-V gametocytes were successfully enriched to >95 %
purity with yields of ~677,500 ± 83,815 gametocytes per
ml original culture volume (n = 4). The assay incubation
time was monitored, with a dramatic decrease in ATP
levels observed directly after enrichment, which then
stabilized around 16–24 h. However, an average decrease
of ~50 % was seen in ATP levels of untreated parasites
Fig. 3 Functionality and viability of gametocytes. a Male exflagellation. White-light, Giemsa and Phalloidin stained real-time imaging of exflagellating
microgamete. Visualized at 200x magnification. b Flow cytometric evaluation of asexual parasites and gametocytes by thiazole orange nuclear marker
analysis. Gametocytes were purified on magnetic columns and treated with xanthurenic acid (XA) to induce exflagellation of male gametes
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0.99 to 0.85 at 48 h. The assay produced good intra-assay
variability with average Z’-factors of 0.84 and 0.79 at 24
and 48 h, respectively. However, a relatively high average
%CV of 8.8 % was observed.
pLDH assay as indicator of metabolic activity in viable
parasites
The pLDH assay relies on the rapid utilization of 3-
acetylpyridine adenine dinucleotide (APAD) as a coen-
zyme by P. falciparum lactate dehydrogenase in the
reaction leading to the conversion of lactate to pyruvate
[35, 46]. The pLDH assay revealed acceptable linearity
profiles of R2 = 0.95 and 0.96 achieved at 0.5 % and 1 %
haematocrit, respectively (Gametocytocidal assay metrics
provided in Additional file 3: Figure S4). At 24 h, the Z’-
factor, S/N and S/B ratios were markedly less than after
48 h of incubation (S/N of 28 vs. 300 at 24 vs. 48 h,
respectively, Table 2). Z’-factor values decreased with
decreasing gametocytaemia and haematocrit with the
optimal gametocytaemia and haematocrit for the pLDHassay determined as 4.5 % gametocytaemia and 0.5 %
haematocrit, based on a Z’-factor of 0.90. However, due
to the typical gametocytaemia produced without enrich-
ment, the assay was optimized to 2 % gametocytaemia
and 1 % haematocrit with an acceptable Z’-factor of 0.87
attained at 2.3 % gametocytaemia and 0.5 % haematocrit.
Average %CV was 2.4 % between independent experi-
ments for the control compounds.
PrestoBlue® assay as an indicator of parasite respiration
PrestoBlue® is a colourimetric reagent whose spectral
features reflect the metabolic activity of cells. It is based
on resazurin, a cell-permeant blue dye, which functions
as a cell viability indicator when reduced to resorufin
(red) by the metabolic activity of living cells. Resazurin
reduction correlates almost perfectly with cellular res-
piration. Resorufin is around 12 times more fluorescent
than resazurin and has an emission maximum of
584 nm [52, 53]. The colourimetric assay displayed a
good linearity profile in the absence or presence of the
drugs tested (R2 = 0.97) using a 2 % gametocytaemia and
Table 2 Performance indicators of various gametocytocidal assay platforms
Assay performance parameters (avg) ATP pLDH PrestoBlue® Luciferase
(n = 4) (n = 4) (n = 4) (n = 4)
S/N >15 000 >300 >900 16 000 (early)
500 (late)
S/B 500 3.2 15 175
Z’-factor (avg) 0.79 0.87 0.91 0.81
%CV (intra-assay) 8.8 % 2.4 % 3.15 % 0.73 %
Avg DHA activity at 1 μM (% inhibition) 37.19 ± 7.67 % 62 ± 6 % 83.48 ± 8.58 % 73.56 ± 5.58 % (avg early/late)
IC50 DHA 14.9 μMa 20 nM 11 nM 43 nM (early)
11 nM (late)
IC50 MB 900 nM
a 800 nM - 195 nM (early)
143 nM (late)
DHA Dihydroartemisinin, MB Methylene blue
aunpaired experiments at 24 h
Each assay was performed after 48 h drug exposure and comparative quality control parameters determined, utilising standardization of DHA activity as common
factor between all the assay platforms. Methylene blue interferes with the PrestoBlue® assay and was not used as control. Data are from 4 independent
experiments (performed in triplicate) for each assay platform
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estimated to be 97 % and 21 %, respectively, and the
average %CV between independent experiments was
estimated to be 3.15 % (Gametocytocidal assay metrics
provided in Additional file 3: Figure S5). On average,
the Z’-factor was estimated to be 0.91 (Table 2). Modify-
ing the final gametocytaemia (using 0.5 %, 1 %, or 3 %),
or by decreasing the drug incubation duration (24 h
instead of 48 h) led to a general reduction in assay per-
formance as determined by the Z’-factor.
Luciferase reporter assay as an indicator of stage-specific
gametocyte gene expression
Two transgenic parasite lines were employed in the
luciferase assays viz. NF54-PfS16-GFP-Luc and NF54-
Mal8p1.16-GFP-Luc [37], expressing a green fluorescent
protein (GFP)-luciferase fusion reporter gene under the
control of two gametocytogenesis-specific genes, Pfs16
NF54Pfs16 luciferase activity peaks on day 2 of gametocy-
togenesis and then gradually declines [54]. Mal8p1.16
reporter expression in NF54mal8p1.16 is specific for late
stage gametocytes, increasing only at day 6–8 and
peaking at day 10–12 after gametocytogenesis [37].
These lines accurately and reproducibly allow detec-
tion and quantification of early (stage I/II) gametocytes
from mature gametocytes (stage IV/V) [37]. Luciferase
activity was determined for a stage I/II culture (day 5;
89 % stage I and II; 11 % stage III; n = 6) as well as ma-
ture stage IV/V gametocytes (day 11; 91 % stage IV/V;
9 % stage III; n = 6). This revealed quantitative evaluation
of the stage distribution of gametocyte populations, inde-
pendent of haematocrit interference (Gametocytocidal
assay metrics provided in Additional file 3: Figure S6).
This assay exhibited good intra-assay reproducibility(Z’-factor of 0.77 and 0.83 on average for early and late
gametocyte markers, average of 0.81) as well as high
sensitivity (S/N >500 or >16 000 for the late and early
marker assays, respectively) and a %CV of 0.73 %
(Table 2).
Assay comparisons for gametocytocidal screens
The different assay platforms were also evaluated and
compared for their ability to accurately determine IC50
of known gametocytocidal compounds DHA and methy-
lene blue. Late stage gametocytocidal potency of DHA
has been reported to be in the range of 2–26 nM
whereas methylene blue potency is poorer, ranging
between 12 and 490 nM [15, 38]. The pLDH, luciferase
reporter and PrestoBlue® assays all reported comparible
low nM activities for DHA whereas the luciferase
reporter assay seemed more sensitive to determine
methylene blue IC50 compared to the pLDH and ATP
assays (Table 2).
Taking assay platform differences into account, and
relying on good intra-assay variability for each assay, the
ATP, pLDH, luciferase reporter and PrestoBlue® assays
were compared in the context of a 10-compound set
provided by MMV (Fig. 4). A single population of
mature stage IV/V gametocytes were produced from P.
falciparum (NF54) and split such that all the assays were
performed in parallel on the same gametocytes. The only
differences were that a proportion of these gametocytes
were enriched to enable the ATP assay. Additionally,
gametocytes were produced in parallel from the
luciferase reporter lines. The remaining parameters for
each assay were all comparable: in each case, single-
point assays were performed at 1 μM drug for 48 h of
continuous drug pressure for at least three replicates in
Fig. 4 Comparative analysis of the performance of four assay platforms for gametocytocidal compounds. Mature stage IV/V gametocytes were
assayed after 48 h continuous exposure to 1 μM drug in the four different assay platforms indicated (luciferase markers for both early (LucEG) and
late gametocytes (LucLG)), based on the optimal conditions for each platform as previously indicated. The ATP data for halofantrine approximated
zero. Data are of at least triplicate experiments, ± SEM
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factors ≥0.8. The assays were performed on mature
stage IV/V gametocytes (>90 % distribution) in all
instances except for the luciferase reporter assay on
early stage gametocytes (>80 % stage II-III parasites).
To enable comparisons, significant inhibition of gameto-
cyte viability is defined as 40–70 % inhibition, 30–40 %
activity is seen as marginal, whereas no activity is defined
as <30 % inhibition.
Although direct comparison of absolute inhibition
values are difficult between assay platforms, similar
trends were observed including comparable performance
of the luciferase marker assay and the PrestoBlue® assay
for compounds such as DHA and methylene blue. At
the concentration tested (1 μM), these compounds
resulted in >70 % inhibition of parasite viability. The
ATP and pLDH assays consistently did not detect the
same level of inhibition of parasite viability for the endo-
peroxides (artemether and DHA, <50 % inhibition) com-
pared to the other assay platforms, however, the luciferase
and PrestoBlue® assays detected >50 % inhibition on these
compounds. Interestingly, only the luciferase reporter
assay detected any activity for OZ439 (>70 % inhibition)
whereas all the other assays defined this compound as
inactive (<30 % inhibition). The ATP assay could not
detect any inhibitory activity for chloroquine and halofan-
trine and may therefore be more sensitive to indicating
the known inability of these compounds to inhibit game-
tocytes. Data from the luciferase reporter assays indicate
that these compounds are indeed not highly active againstmature gametocytes (30–50 % inhibition at 1 μM). The
signal obtained for these compounds in the PrestoBlue®
assay may therefore rather reflect the inability of this
assay in discriminating activity of compounds against
earlier stages of gametocytes, whereas the ATP assay
(working on an enriched mature stage gametocyte
population) more accurately reflects these compounds’
activity. The PrestoBlue® and pLDH assays seem to
provide what may be falsely enhanced activity for
compounds such as tafenoquine and lumefantrine,
respectively. However, the PrestoBlue® assay did not
correlate to the other assays for Atovaquone, reporting
poor activity of this compound.Discussion
Sustainable malaria control dictates the integration of
therapeutic strategies targeting the pathogenic asexual
forms as well as the transmissible sexual gametocyte
forms of malaria parasites. Drug discovery is a long,
arduous and expensive process, and to avoid duplication
in screening libraries for gametocytocidal compounds,
especially in the face of limited resources, it would be
useful to compare assay results generated in different
laboratories. Currently there are often discrepancies in
the data, which hampers progress in this field. Two
major challenges in this regard are the lack of
standardization in: 1) culturing reproducible batches of
pure, stage-specific gametocytes in high yield and 2)
assays for the metabolically hypo-active gametocytes.
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Gametocytogenesis can be mimicked in vitro under very
diverse conditions, which makes standardization difficult
and also reflects our lack of knowledge of the in vivo
biological process by which P. falciparum parasites
generate gametocytes. One of the major problems with
current gametocyte production protocols is that they are
frequently not reproducible, and are not robust when
applied in different settings. Furthermore, the inherent
biological variability in different parasite populations in
culture introduces additional challenges. In this study a
protocol was optimized, which consistently generated
high quality gametocytes in three different laboratories,
confirming the robustness of the method. These game-
tocytes were used to evaluate and directly compare
different screening assays using a set of 10 drugs
supplied by MMV. The method exploited the inherent
biological conversion of asexual parasites to gameto-
cytes, confirming that not all asexual parasites will con-
vert to gametocytes even under optimal conditions.
Recently, gametocyte conversion has been shown to be
under a transcriptional regulator (PfAp2G) that is acti-
vated in a stochastic manner, leading to a normally low
frequency (~12.5 %) of gametocyte conversion [55]. The
high conversion of approximately 33 % obtained in the
current study therefore points to the direct response of
the parasites to external stressors to obtain at least a
doubling in gametocyte conversion in the in vitro
system. The increased production of gametocytes did
not change the gender ratio of approximately 4:1 females:-
males as has been observed in vivo [8, 11]. For gameto-
cytes produced in vitro to be used to evaluate the
gametocytocidal activity of compound libraries, it is im-
portant to monitor the quality of the parasites prior to
performing the assay, including assessment of gametocyte
viability and functionality (e.g. ability to form male gam-
etes); purity (absence of asexual parasites) and stage-
specificity (>90 % of stage IV/V in this study).
Gametocytocidal screening assays
Endeavours to find transmission blocking anti-malarials
are currently hindered by a lack of understanding of the
basic biological processes governing gametocytogenesis
in the human host, which makes an informed choice of
an assay system problematic. In humans, gametocytes
are suggested to be terminally differentiated and meta-
bolically less active [32]. It is proposed that there is no
replication of the gametocyte genome during develop-
ment and that gametocytes are arrested in phase G0 of
the cell cycle [56]. Nucleic acid synthetic activity is likely
restricted to RNA synthesis and genetic evidence shows
that gametocytes are haploid. Synthesis of RNA is
reported to stop after day 6 of development, and there is
no haemoglobin digestion and protein synthesis inmature gametocytes [57, 58]. Any assay for gametocyto-
cidal activity therefore currently relies on measuring
changes in metabolic status or stress responses in game-
tocytes, performed against the background of a meta-
bolically ‘inactive’ cell.
Several groups have published platforms allowing the
evaluation of gametocytocidal activity of a compound
series. A Bill and Melinda Gates Foundation Initiative
recently attempted to compare gametocyte assay plat-
forms from various laboratories using different assay
readouts (reported elsewhere). However, direct com-
parison of the data from these studies is fraught with
difficultly due to differences in parameters such as: 1)
parasite strains used; 2) different gametocyte induction
protocols; 3) composition of culture medium used; 4)
gametocyte isolation protocols; 5) stage of development
of gametocytes; 6) assay platforms; 7) presence or
absence of erythrocytes; 8) number of gametocytes per
assay well; 9) panel of compounds; 10) concentration of
compounds; 11) drug exposure times; 12) presentation
of data, e.g. % inhibition at single concentrations or only
IC50 values, etc.
The production of viable and functional gametocytes
using a standardized, robust gametocyte production
protocol was used here to overcome the limitations
listed above. These gametocytes were subsequently used,
for the first time, in a parallel, comparative interrogation
of four different gametocytocidal assays (ATP, pLDH,
PrestoBlue® and the luciferase reporter) for their ability
to detect gametocytocidal activity of a single set of 10
compounds from MMV. The compound set was pro-
vided blinded and only unblinded after completion of all
the assays and data analysis. The parallel nature of the
assays performed on the same gametocyte population
uniquely allowed direct comparisons of the assay plat-
forms in this study.
Comparison of assays that evaluate different biological
functions
The tricarboxylic acid (TCA) cycle is highly active in
gametocytes, especially in females that are characterized
by a rapidly expanding mitochondrion in preparation for
gametogenesis [59, 60]. A recent study found 15 of 16
mRNA transcripts of mitochondrial TCA cycle enzymes
upregulated in gametocytes [50]. Increased TCA cycle
activity implies increased levels of cytoplasmic ATP. In
the luminescent ATP assay, ATP content is used to
evaluate the functional integrity of living cells, as
injured/dead cells will display drastically reduced ATP
levels [61]. This platform should, therefore, be reliable
for the assessment of compounds for their ability to
inhibit gametocytes. However, the assay requires the
downstream manipulation of gametocytes (enrichment
and isolation) during which gametocyte viability is
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within the first 16 h after enrichment, and this level
steadily decreases as gametocytes are further incubated
after enrichment to a total level of only 20 % remaining
at 48 h, which is the usual timeframe for assaying drug
effects. This then influences the number of viable game-
tocytes remaining in the population used to detect drug
effects. Moreover, although this manipulation results in
high S/N ratios due to gametocytes being enriched above
background, it could contribute to higher inter-assay
variability. However, the ATP assay is possibly less prone
to artefacts compared to fluorescent viability assays [62].
One major advantage of the pLDH assay is that it is
performed directly on parasite cultures, therefore mini-
mising manipulation of gametocytes. pLDH has been
shown to be present in the blood of malaria patients and
to be a reliable marker for gametocyte viability as the
enzyme is present at high levels throughout gametocyto-
genesis [63, 64]. pLDH catalyses the conversion of pyru-
vate, the final product of glycolysis, to lactate. This flux
is important for the regeneration of NAD+, itself an
essential cofactor for glycolysis. Only when increased
fermentative glycolysis is possible, do cells exhibit in-
creased proliferation through the anabolic capacity of
glycolysis [65]. However, late stage gametocytes exhibit
decreased expression of genes responsible for glycolysis,
protein biosynthesis and haemoglobin catabolism [50].
As mentioned, terminally differentiated gametocytes
make use of a canonical TCA cycle, and less glucose is
metabolized by fermentation to lactate. Reduced glyco-
lytic activity suggests that less pyruvate is converted to
lactate by LDH, which might explain the relatively low
S/B values obtained for the pLDH assay. A direct com-
parison of the pLDH activity in asexual parasites, early
and late stage gametocytes will be valuable in confirm-
ation of assay reliability. Additionally, the continued
presence of pLDH activity even after parasite death has
to be taken into account [34].
Redox reactive (oxidoreductive indicators) cell per-
meable dyes like alamarBlue® and PrestoBlue® have
previously been reported as robust assays amenable to
high-throughput screens, more sensitive than traditionally
used tetrazolium dyes [31, 41]. These assays enable ease of
use when screening gametocyte populations. However,
care must be taken with these assay platforms in the case
where compounds target the redox state of the parasite, as
it may interfere with the assay readout. Moreover, com-
pounds routinely used like methylene blue cannot be used
in this assay platform due to colourimetric interference.
Despite the drawbacks of each assay, the ATP, pLDH
and PrestoBlue® assays are useful for assaying gametocyto-
cidal activity of compounds on non-genetically modified
lab strains as well as clinical isolates. This information will
become increasingly important in drug developmentprogrammes, enabling early detection of cross-resistance
or efficacy failure of lead gametocytocidal compounds.
Assay cascades may also be influenced from an economic
point of view, with the PrestoBlue® the least expensive
(~$1 per compound) followed by the pLDH and lastly the
luminescence ATP and luciferase assays (up to a 7-fold in-
crease in cost).
Compared to the assays above, the bioluminescent
luciferase reporter lines enabled stage-specific gametocy-
tocidal activity detection through endogenous luciferase
production under stage-specific reporters, again with
minimal interference of the luminescent signal by the
compounds screened. This assay platform was robust in
all cases resulting in high S/N ratios and in quantifica-
tion of the internal signal. This platform has recently
been further optimized to a dual-colour assay to
simultaneously and quantitatively assay the viability of
different stages of gametocyte populations [66].
In addition to the above, the blinded nature of the
study and the fact that the assays were performed in
parallel allow for a situation where assay platforms can
be compared directly. The data were validated since the
DHA control included in the study correlated very well
for all assay platforms with the blinded DHA control in-
cluded in the compound panel.
As reported [35, 38], the endoperoxides were able to
equally target both the early- and late-stage gametocytes
and were the most active compounds tested with IC50s
in the nM range in some assay platforms. The equipo-
tency of the endoperoxides to early- and late-stage
gametocytes was confirmed here particularly with the
luciferase reporter assay (for artemether, DHA and
OZ439). These data are also comparable to the late-stage
gametocytocidal activity of endoperoxides (artemether
and DHA) [34]. The endoperoxides are amongst the most
potent anti-malarials, fast acting and thought to act
through alkylation of haem or other biomolecules [67]
and requiring iron-mediated activation of the endoper-
oxide bridge. The ability of artemisinins particularly to
oxidize cofactors of parasite flavoenzymes contributes
to generating cytotoxic metabolites and reactive oxygen
species, resulting in oxidative damage to cells [68, 69].
The PrestoBlue® assay was able to detect comparable
levels of activity to the luciferase reporter assay particu-
larly for DHA, indicating that the oxidoreductive dye is
able to measure drug response in the context of oxida-
tive cellular stress, at least for the compounds tested
here. It has however been postulated that another target
for the endoperoxides may be direct interaction with
PfATP6, interfering with ATP synthesis [69]. As mature
gametocytes do not metabolize haemoglobin effectively,
the latter may indeed be the physiological mode of
action of these compounds in the sexual parasites.
Interestingly, the ATP assay indicated poor activity of
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PrestoBlue® assays, previously reported as well [21, 33].
Within the endoperoxide group, OZ439 was shown to
have potent gametocytocidal activity with the luciferase
reporter assay in the low nM range, however, none of the
other assay platforms were able to detect this activity. This
confirmation of the ability of the endoperoxides to target
both immature and mature gametocytes sheds light on
artemisinin-based combination therapy as transmission
blocking drugs, an effect that should not solely be ascribed
to the extremely rapid clearance of asexual parasites and
young gametocytes. Surprisingly, the endoperoxides seem
to exclusively target male gametocytes preventing male
gamete formation; the exact reason for this is unclear [70].
The ATP assay has been reported to be a poor indicator
of the gametocytocidal activity of endoperoxides [21, 33]
and this was confirmed here with IC50s of 15 μM obtained
for DHA compared to nanomolar IC50s seen with the
pLDH, PrestoBlue® and luciferase assays. Alternatively,
gametocytes may stay viable in the presence of endoper-
oxides or at least maintain their ATP pool and LDH
activities while some gene promoters are not as active,
explaining the difference between reporter gene and
metabolic readouts.
The 4-aminoquinolines (chloroquine) were confirmed
to be more active against asexual parasites and early
stage gametocytes, confirming their targeting of haemo-
zoin formation in these stages of the parasite. Whilst the
PrestoBlue® and pLDH assays did seem to indicate some
activity against late-stage parasites, the ATP assay is
possibly more informative for this chemotype. Compara-
tively, the 8-aminoquinolines tested here (primaquine
and tafenoquine) performed poorly against both early
and late stage gametocytes. However, for these com-
pounds, the ATP assay was able to detect low inhibitory
activities, implying differences in the mode of action
between the 4- and 8-aminoquinolines on mature game-
tocytes or interference of the compounds tested (prima-
quine and tafenoquine) with the assay platform.
The 8-aminoquinolines are known to be metabolically
activated by liver enzymes, hence eliciting activity
against liver stage hypnozoite forms of malaria parasites
[71]. However, in the assay systems employed here,
such metabolic activation is not possible but could be
resolved by pre-exposure of the drugs to liver cell
extracts before analysing their gametocytocidal activity.
Needless to say, such metabolic activation is not
considered in medium- to high-throughput screening
assays of unknown compounds. However, the PrestoBlue®
assay seems to report ‘enhanced’ activity of particularly
tafenoquine compared to the other assay systems used,
but this is not the case for primaquine. Primaquine is
known to have activity against liver stages of P. falciparum,
Plasmodium vivax and Plasmodium ovale and is, therefore,of interest in transmission blocking strategies. Prima-
quine has been shown to be gametocytocidal against all
Plasmodium species for late stage gametocytes through
targeting the parasites’ mitochondria, but is not clinic-
ally useful against P. falciparum asexual stages. How-
ever, at in vitro gametocytocidal IC50 values of 1-15 μM
[15, 72], this compound would be identified as not
active, as confirmed by the data presented here (<50 %
inhibition observed on all assay platforms). This dis-
crepancy between activity observed in vivo and the lack
thereof in vitro supports the notion of metabolic activa-
tion of primaquine in vivo and thus hampers the use of
in vitro assay systems for this class of compounds.
The naphthoquinone atovaquone was able to inhibit
~50 % of particularly immature gametocytes with previous
proposed actions including the targeting of the electron
transport chain through the cytochrome b ubiquinol oxi-
dation site [73]. Gametocytes do however have active
mitochondria [8, 65] and according to the ATP levels
measured, these parasites are still 50 % viable and may in-
dicate static arrest of the gametocytes after atovaquone
treatment. The PrestoBlue® assay was unable to detect this
inhibitory capacity at a primary screening concentration
of 1 μM, which may be a concern when such assay plat-
forms are solely used to derive chemical signatures of
libraries for gametocytocidal activity [35, 42]. As this assay
supposedly provides a direct readout of cellular respir-
ation, this is either a more sensitive probe of decreased
glycolysis and respiration of the parasite upon atovaquone
treatment or an indication of pluri-pharmacology of atova-
quone in gametocytes. When atovaquone was rescreened
against the PrestoBlue® assay at 10 μM, gametocytocidal
activity was however noted for this compound (71 +/-
1.9 % inhibition), highlighting the need to define an optimal
concentration threshold for primary screens that minimizes
both false-negative and false-positive hit rates. In the case
of synthetic compound library screens, the effects of false-
negative losses may be lessened if related compounds of the
same basic scaffold are identified to be active [74].
Conclusions
The standardized protocol produced a reproducible,
high gametocytaemia and these parasites were viable,
functional and could be used in gametocytocidal assays.
An important point that emerged from this study is that
unlike asexual parasite assays measuring parasite prolifera-
tion, greater variability in end-point readout exists between
gametocytocidal assays that interrogate different parasite
biological functions. Drug mode of action is likely to be an
important factor in this outcome. This suggests that
compounds targeting a specific biological pathway may fail
in one assay, but be active when evaluated in a different
assay. Reliance on a single assay platform to screen different
pharmacophores may therefore result in false negative
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be sensitive to a particular pharmacophore/mode-of-action
may be used to screen compounds of the same series and
additionally provide data that is informative from a bio-
logical perspective and may provide indications of the drug
mode of action. This does highlight the care that must be
taken when screening broad chemotypes with a single assay
platform against gametocytes for which the biology is not
clearly understood.
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